These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 22079329)

  • 1. CETP inhibition in perspective.
    Stock J
    Atherosclerosis; 2012 Feb; 220(2):325-8. PubMed ID: 22079329
    [No Abstract]   [Full Text] [Related]  

  • 2. [HDL and CETP in atherogenesis].
    Pöss J; Böhm M; Laufs U
    Dtsch Med Wochenschr; 2010 Feb; 135(5):188-92. PubMed ID: 20082258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Future of cholesteryl ester transfer protein inhibitors.
    Rader DJ; deGoma EM
    Annu Rev Med; 2014; 65():385-403. PubMed ID: 24422575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is a blood pressure rise the only deleterious off-target effect of cholesterol ester transfer protein inhibitors?
    Miura S; Saku K
    J Hypertens; 2010 Aug; 28(8):1614-6. PubMed ID: 20647856
    [No Abstract]   [Full Text] [Related]  

  • 5. Anacetrapib: hope for CETP inhibitors?
    Gurfinkel R; Joy TR
    Cardiovasc Ther; 2011 Oct; 29(5):327-39. PubMed ID: 20406242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial.
    Lüscher TF; Taddei S; Kaski JC; Jukema JW; Kallend D; Münzel T; Kastelein JJ; Deanfield JE;
    Eur Heart J; 2012 Apr; 33(7):857-65. PubMed ID: 22345126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of cholesteryl ester transfer protein inhibitor on vitamin E transport should be studied.
    Masterjohn C
    Am Heart J; 2009 Jul; 158(1):e11; author reply e13. PubMed ID: 19540377
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects of dalcetrapib in patients with a recent acute coronary syndrome.
    Schwartz GG; Olsson AG; Abt M; Ballantyne CM; Barter PJ; Brumm J; Chaitman BR; Holme IM; Kallend D; Leiter LA; Leitersdorf E; McMurray JJ; Mundl H; Nicholls SJ; Shah PK; Tardif JC; Wright RS;
    N Engl J Med; 2012 Nov; 367(22):2089-99. PubMed ID: 23126252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation: Concordance With Clinical Outcomes.
    Tardif JC; Rhainds D; Brodeur M; Feroz Zada Y; Fouodjio R; Provost S; Boulé M; Alem S; Grégoire JC; L'Allier PL; Ibrahim R; Guertin MC; Mongrain I; Olsson AG; Schwartz GG; Rhéaume E; Dubé MP
    Circ Cardiovasc Genet; 2016 Aug; 9(4):340-8. PubMed ID: 27418594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholesterylestertransfer protein inhibition and endothelial function in type II hyperlipidemia.
    Hermann F; Enseleit F; Spieker LE; Périat D; Sudano I; Hermann M; Corti R; Noll G; Ruschitzka F; Lüscher TF
    Thromb Res; 2009; 123(3):460-5. PubMed ID: 18789492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of cholesteryl ester transfer protein inhibitors on human lipoprotein metabolism: why have they failed in lowering coronary heart disease risk?
    Schaefer EJ
    Curr Opin Lipidol; 2013 Jun; 24(3):259-64. PubMed ID: 23652567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mulling over the odds of CETP inhibition.
    von Eckardstein A
    Eur Heart J; 2010 Feb; 31(4):390-3. PubMed ID: 20097704
    [No Abstract]   [Full Text] [Related]  

  • 13. Are human CETP mutations and CETP-inhibiting drugs a good or a bad deal?
    Luft FC
    J Mol Med (Berl); 2006 Aug; 84(8):625-7. PubMed ID: 16855847
    [No Abstract]   [Full Text] [Related]  

  • 14. JTT-705: is there still future for a CETP inhibitor after torcetrapib?
    Rennings AJ; Stalenhoef A
    Expert Opin Investig Drugs; 2008 Oct; 17(10):1589-97. PubMed ID: 18808319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dalcetrapib , a cholesteryl ester transfer protein modulator.
    Hooper AJ; Burnett JR
    Expert Opin Investig Drugs; 2012 Sep; 21(9):1427-32. PubMed ID: 22725099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on CETP inhibition.
    Davidson MH
    J Clin Lipidol; 2010; 4(5):394-8. PubMed ID: 21122682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increasing high-density lipoprotein cholesterol by cholesteryl ester transfer protein-inhibition: a rocky road and lessons learned? The early demise of the dal-HEART programme.
    Landmesser U; von Eckardstein A; Kastelein J; Deanfield J; Lüscher TF
    Eur Heart J; 2012 Jul; 33(14):1712-5. PubMed ID: 22696435
    [No Abstract]   [Full Text] [Related]  

  • 18. Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents.
    Shinkai H
    Expert Opin Ther Pat; 2009 Sep; 19(9):1229-37. PubMed ID: 19663630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of CETP inhibition in dyslipidemia.
    El Harchaoui K; van der Steeg WA; Stroes ES; Kastelein JJ
    Curr Atheroscler Rep; 2007 Aug; 9(2):125-33. PubMed ID: 17877921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anacetrapib, a cholesterol ester transfer protein (CETP) inhibitor for the treatment of atherosclerosis.
    Masson D
    Curr Opin Investig Drugs; 2009 Sep; 10(9):980-7. PubMed ID: 19705341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.